TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23534775

Group type: EXPERIMENTAL
Intervention: Granisetron injection as primary prophylaxis
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-granisetron group
Number of subjects: 96
Study: 21221620

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI) - 4 sequential injections within 2 weeks after systemic steroids
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group - no further medications after systemic steroids
Number of subjects: 46
Study: 18320015

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both on-pump and off-pump surgery
Number of subjects: 40
Study: 17205816

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with cervical plexus block (CPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cervical plexus block (CPB) alone
Number of subjects: 60
Study: 14664881

Group type: EXPERIMENTAL
Intervention: Arimidex (anastrozole) alone or in combination with tamoxifen
Number of subjects: 285

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 285
Study: 10809459

Group type: EXPERIMENTAL
Intervention: ICU stays of 14 days or longer
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Discussion of care preferences with physicians
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Patients preferring palliative care
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Patients with long ICU stays
Number of subjects: 1494
Study: 8776638

Group type: EXPERIMENTAL
Intervention: Low-dose heparin management (100 IU/kg i.v. and 0 to 1,000 IU/L priming; target ACT over 180 seconds)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-dose heparin management (300 IU/kg i.v. and 5,000 IU/L priming; target ACT over 480 seconds)
Number of subjects: 24
Study: 1595228

Group type: EXPERIMENTAL
Intervention: EHRZ regimen
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: SHRZ regimen
Number of subjects: 178

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 178
Study: 6429872

Group type: EXPERIMENTAL
Intervention: Intravenous feeding with amino acid dextrose solutions and fat emulsions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard postoperative care (unfed group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous feeding
Number of subjects: 34
Study: 31655622

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5-10 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28251811

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Dexamethasone 0.7 mg
Number of subjects: 244
Study: 26761395

Group type: EXPERIMENTAL
Intervention: Single Ring Isolation (SRI)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Wide Antral Isolation (WAI)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Comparison between SRI and WAI
Number of subjects: 187
Study: 25123605

Group type: EXPERIMENTAL
Intervention: Web-based Patient Reported Outcomes (PRO) collection
Number of subjects: 47

Group type: COMPARATOR
Intervention: Paper Patient Reported Outcomes (PRO) collection
Number of subjects: 47
Study: 22424026

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion of ≥4 U
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: CABG-related major bleeding
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Allogeneic blood product transfusions
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: 1-year mortality
Number of subjects: 1491
Study: 20383533

Group type: EXPERIMENTAL
Intervention: VAM-solo-surgeon living donor nephrectomy (SLDN)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional VAM-human-assisted living donor nephrectomy (HLDN)
Number of subjects: 82
Study: 17352866

Group type: EXPERIMENTAL
Intervention: Tongxia Huayu Decoction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (normal treatment)
Number of subjects: 53
Study: 16229633

Group type: EXPERIMENTAL
Intervention: Mid-infrared spectroscopy
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 247

Group type: COMPARATOR
Intervention: Mid-infrared and Raman spectroscopy
Number of subjects: 247
Study: 11895165

Group type: EXPERIMENTAL
Intervention: Lycasin HBC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrogenated polysaccharide fraction of Lycasin HBC
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 9
Study: 9989713

Group type: EXPERIMENTAL
Intervention: Active Training (AT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Physiotherapy Treatment (PT)
Number of subjects: 68
Study: 7774213

Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2148341

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily in three divided doses)
Number of subjects: 8
Study: 7306966

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, 400 mg/sq m; methotrexate, 30 mg/sq m; and 5‐FU, 500 mg/sq m, given i.v. every 2 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU, 500 mg/sq m i.v. every week)
Number of subjects: 62
Study: 31041717

Group type: EXPERIMENTAL
Intervention: Carboplatin/nab-paclitaxel (+/- bevacizumab)
Number of subjects: 10
Study: 31551226

Group type: EXPERIMENTAL
Intervention: Carvedilol combined with conventional therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 180
Study: 28041757

Group type: EXPERIMENTAL
Intervention: iGEL supraglottic airway
Number of subjects: 46

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 46
Study: 25932657

Group type: EXPERIMENTAL
Intervention: Contact (CON)
Number of subjects: 19
Study: 23701010

Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction and supragingival scaling (treatment group, n = 26)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No periodontal treatment (control group, n = 29)
Number of subjects: 55
Study: 21889802

Group type: EXPERIMENTAL
Intervention: Behavior or cognitive therapy (16 sessions) with fluvoxamine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Behavior or cognitive therapy (16 sessions) without fluvoxamine
Number of subjects: 121
Study: 19688313

Group type: EXPERIMENTAL
Intervention: Ningdong Granule (NDG) plus haloperidol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 90
Study: 18637764

Group type: EXPERIMENTAL
Intervention: P. ginseng and warfarin (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Warfarin only (n = 13)
Number of subjects: 25
Study: 16131290

Group type: EXPERIMENTAL
Intervention: T/S needles placed in traditional sites with manual needle stimulation (n = 29)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: T/0 traditional needle location without stimulation (n = 30)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: N/S needles inserted in nontraditional locations with stimulation (n = 28)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: N/0 nontraditional needle location without stimulation (n = 27)
Number of subjects: 114
Study: 12325097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10095815

Group type: EXPERIMENTAL
Intervention: Mid-morning snack served 2 hours after insulin injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: No mid-morning snack served
Number of subjects: 28
Study: 8530976

Group type: EXPERIMENTAL
Intervention: Spinal cord MRI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Visual EPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Median somatosensory EPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tibial somatosensory EPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Motor EPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brain-stem acoustic EPs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSF oligoclonal bands (OBs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Short-term clinical outcome
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tibial somatosensory EP and motor EP abnormalities
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Long-term clinical follow-up (mean duration 24 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Presence of CSF OBs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EPs exploring spinal cord function
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined use of brain MRI and CSF OBs
Number of subjects: 27
Study: 2192444

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 13
Study: 721787

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 36
Study: 31615177

Group type: EXPERIMENTAL
Intervention: Rehabilitation combined with selective lumbosacral posterior rhizotomy (SPR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 47
Study: 27740732

Group type: EXPERIMENTAL
Intervention: Four novel mutations identified: DNMT3A rs2304429 (24.74%), CYP1A1 rs3826041 (47.35%), STX1B rs72800847 (7.01%), NQO1 rs10517 (36.11%)
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Addition of four mutations to the regression model
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Novel mutations identified
Number of subjects: 1617
Study: 25484310

Group type: EXPERIMENTAL
Intervention: Stempeucel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23384679

Group type: EXPERIMENTAL
Intervention: QbG10
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21518924

Group type: EXPERIMENTAL
Intervention: ΔSUVmaxPET0-2 (> 66%)
Number of subjects: 85

Group type: COMPARATOR
Intervention: ΔSUVmaxPET0-2 (≤ 66%)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ΔSUVmaxPET0-4 (> 70%)
Number of subjects: 85

Group type: COMPARATOR
Intervention: ΔSUVmaxPET0-4 (≤ 70%)
Number of subjects: 85
Study: 18294568

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Statin therapy (secondary prevention)
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Statin therapy (new-onset or postoperative AF)
Number of subjects: 3557
Study: 16808579

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (RMGIC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: APC bracket (resin)
Number of subjects: 60
Study: 14640133

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CABG with cardiopulmonary bypass (CPB)
Number of subjects: 20
Study: 10780036

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 20
Study: 8837910

Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 1339211

Group type: EXPERIMENTAL
Intervention: ACTH stimulation in tubercular patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 28
Study: 6536513

Group type: COMPARATOR
Intervention: Control (Group I: no glycopyrrolate or cimetidine)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (Group II: 5 micrograms kg‐1 intramuscularly in a.m.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (Group III: 5 mg kg‐1 orally in a.m.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (Group IV: 5 mg kg‐1 orally in a.m. and glycopyrrolate 5 micrograms kg‐1 in a.m.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (Group V: 5 mg kg‐1 orally h.s. and a.m.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (Group VI: as in Group V and glycopyrrolate as in Group II)
Number of subjects: 96
Study: 30730980

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 1501
Study: 30419931

Group type: EXPERIMENTAL
Intervention: Practice cognitive control by delaying their first cigarette of the day for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monitoring only (no practice group)
Number of subjects: 80
Study: 26684960

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention (Alcohol-Wise)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 58
Study: 25248854

Group type: EXPERIMENTAL
Intervention: Presentation encouraging employers to purchase a high quality depression product with a return on investment estimate
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care presentation encouraging employers to work with their health plan to improve depression treatment quality indicators
Number of subjects: 293
Study: 22752636

Group type: EXPERIMENTAL
Intervention: GFD + prednisolone (1 mg/kg for 4 weeks, n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: GFD (n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GFD + prednisolone (1 mg/kg for 4 weeks)
Number of subjects: 33
Study: 20472748

Group type: EXPERIMENTAL
Intervention: 180° SLT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 360° SLT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated eyes)
Number of subjects: 40
Study: 18550198

Group type: EXPERIMENTAL
Intervention: KRM group (AST-120)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 16019771

Group type: EXPERIMENTAL
Intervention: Finasteride (3 months pretreatment)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (3 months pretreatment)
Number of subjects: 35
Study: 12203177

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10609766

Group type: EXPERIMENTAL
Intervention: Diabetic patients (Group A)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Nondiabetic patients (Group B)
Number of subjects: 673
Study: 8604367

Group type: EXPERIMENTAL
Intervention: Special care unit (SCU) for chronically critically ill patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional ICU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 0
Study: 1941059

Group type: EXPERIMENTAL
Intervention: Intensive cytarabine and daunorubicin (DNR)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cycles of mercaptopurine (6‐MP) and methotrexate (MTX), followed by 6MP, MTX, vincristine (VCR), and prednisone for 3 years
Number of subjects: 151
Study: 7150496

Group type: EXPERIMENTAL
Intervention: Inhalation of fenoterol aerosol (400 micrograms)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buccal administration of fenoterol (400 micrograms)
Number of subjects: 19
Study: 29979882

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST; n = 95)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Group Counseling (GC; n = 91)
Number of subjects: 186
Study: 29912955

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 132
Study: 27871538

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1‐μg/kg load followed by 1‐μg/(kg h) infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol infusion at 300 μg/(kg min) reduced to 250‐μg/(kg min) infusion
Number of subjects: 40
Study: 24291194

Group type: EXPERIMENTAL
Intervention: HOWARU(®) Restore probiotic 1.70×10(10) CFU (high-dose, n=168)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: HOWARU(®) Restore probiotic 4.17×10(9) CFU (low-dose, n=168)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo (n=167)
Number of subjects: 503
Study: 22580935

Group type: EXPERIMENTAL
Intervention: Interval training on VR simulation over 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Massed training on VR simulation in 1 day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition performing laparoscopic assessment task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Practice condition with 1 complete practice trial on the simulator
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-practice condition
Number of subjects: 40
Study: 20236345

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 16
Study: 17608817

Group type: EXPERIMENTAL
Intervention: Pituitary disease patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Endocrine disease patients (pituitary or nonpituitary)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nonpituitary endocrine patients
Number of subjects: 86
Study: 15836978

Group type: EXPERIMENTAL
Intervention: Noxious stimulation (30% above pain threshold)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Innocuous stimulation (30% below pain threshold)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Noxious stimulation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 4
Study: 12046068

Group type: EXPERIMENTAL
Intervention: Preoperative regional artery chemotherapy (PRACT)
Number of subjects: 110
Study: 10459075

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate administration (CHO-H)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo drink (placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate administration (CHO-C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fasted group
Number of subjects: 16
Study: 7608279

Group type: EXPERIMENTAL
Intervention: L-Arginine infusion (500 mg/kg over 30 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline vehicle
Number of subjects: 10
Study: 2193166

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg per day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 499288

Group type: EXPERIMENTAL
Intervention: Oral aminophylline 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aminophylline suppository 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30999952

Group type: COMPARATOR
Intervention: SMS text message intervention plus Treatment As Usual (TAU) receiving nine SMS text messages at 1, 2, 3, 4, 5, 6, 8, 10 and 12 months post-discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) alone.
Number of subjects: 0
Study: 27917593

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological treatment 2
Number of subjects: 0
Study: 25935596

Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (FU)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (tumors without treatment failure)
Number of subjects: 336
Study: 23390125

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 20881878

Group type: EXPERIMENTAL
Intervention: Creatine (5 g·d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19563393

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily (S80)
Number of subjects: 36
Study: 16452264

Group type: EXPERIMENTAL
Intervention: Operative treatment of medial collateral ligament injury (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonoperative treatment of medial collateral ligament injury (n = 24)
Number of subjects: 47
Study: 15623698

Group type: EXPERIMENTAL
Intervention: Cognitive-motor intervention (CMI) with psychosocial support
Number of subjects: 84

Group type: COMPARATOR
Intervention: Psychosocial support alone (control group)
Number of subjects: 84
Study: 11353935

Group type: EXPERIMENTAL
Intervention: BIPAP (n = 11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Assisted spontaneous breathing (ASB) (n = 7)
Number of subjects: 18
Study: 10963910

Group type: EXPERIMENTAL
Intervention: Stages of change questionnaire
Number of subjects: 177
Study: 8972892

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 to 50 mg twice daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Beta-blockers (atenolol: 25 to 100 mg once daily or propranolol: 10 to 80 mg twice daily)
Number of subjects: 149
Study: 1292407

Group type: EXPERIMENTAL
Intervention: Preoxygenation with 50% oxygen and nitrous oxide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Preoxygenation with 100% oxygen
Number of subjects: 65

Group type: COMPARATOR
Intervention: No preoxygenation (Control Group)
Number of subjects: 65
Study: 6467836

Group type: EXPERIMENTAL
Intervention: Supine rest for 20 minutes followed by standing transition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supine rest for 1 minute followed by standing transition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-up tilt after supine rest
Number of subjects: 0
Study: 30503307

Group type: EXPERIMENTAL
Intervention: High-flexion mobile-bearing TKA
Number of subjects: 164

Group type: COMPARATOR
Intervention: High-flexion fixed-bearing TKA
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study: 29727039

Group type: EXPERIMENTAL
Intervention: Diabetes with microvascular complications
Number of subjects: 2707

Group type: EXPERIMENTAL
Intervention: Diabetes without microvascular complications
Number of subjects: 2707

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 2707
Study: 26861976

Group type: EXPERIMENTAL
Intervention: EMLA topical anaesthetic (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ametop topical anaesthetic (4% tetracaine)
Number of subjects: 11
Study: 24379278

Group type: EXPERIMENTAL
Intervention: Diuretic efficiency (DE) estimated as net fluid output produced per 40 mg of furosemide equivalents, dichotomized into high versus low DE.
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Traditional baseline characteristics and metrics of renal function and preadmission diuretic therapy.
Number of subjects: 1047